Literature DB >> 9250302

Cytomorphologic evidence of human papillomavirus infection in smears from the irradiated uterine cervix.

A Longatto Filho1, M Y Maeda, M S Oyafuso, V A Alves, C T Kanamura, J Bortolan.   

Abstract

OBJECTIVE: To report the cytomorphologic evidence of human papillomavirus (HPV) infection in cervical smears from women treated with radiotherapy for carcinoma of the uterine cervix. STUDY
DESIGN: From January 1986 to December 1993, 32 cervical cytologic smears (CCSs) from women who had received radiotherapy (Rtx) for squamous cell cervical carcinoma at A.C. Camargo Cancer Hospital were selected for study due to the presence of signs of HPV infection. Review of the files of these patients showed 22 additional samples, which we included in this study. The avidinbiotin-immunoperoxidase technique was performed on previously stained slides using polyclonal rabbit antibovine papillomavirus type 1 to confirm the HPV infection.
RESULTS: Positive reactions were found in 18 cases (27 samples), mainly in cells with classic koilocytotic features, but also in epithelial cells that lacked cytopathic effects. Only one case, a biopsy from a verrucous lesion observed after Rtx, was found to be positive for HPV 6/11 DNA by in situ hybridization.
CONCLUSION: Cytologic and immunohistochemical positivity for HPV, as well as the reaction with a HPV 6/11 DNA probe, strongly suggested that HPV infection was acquired or expressed after radiotherapy. Further studies are needed to assess the mechanisms responsible for such an association.

Entities:  

Mesh:

Year:  1997        PMID: 9250302     DOI: 10.1159/000332791

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  1 in total

1.  Cervicovaginal cytology in patients undergoing pelvic radiotherapy using the Focalpoint system: results from the RODEO study.

Authors:  Maíra Degiovani Stein; José Humberto T G Fregnani; Cristovam Scapulatempo-Neto; Adhemar Longatto-Filho
Journal:  Diagn Pathol       Date:  2015-01-16       Impact factor: 2.644

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.